Wall Street Zen Upgrades Kalaris Therapeutics (NASDAQ:KLRS) to Hold

Kalaris Therapeutics, Inc. (KLRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates Patient dosing is ongoing in the Phase 1b/2 study of TH103; preliminary data anticipated in 1H 2027 Potential Phase 3 clinical trials remain on track for initiation by year-end 2027 $

Kalaris Therapeutics (NASDAQ:KLRS) said expanded Phase 1a data for TH103 in neovascular age-related macular degeneration showed vision and retinal-anatomy improvements, with intraocular retention suggested by plasma pharmacokinetics. The company reported 41% of treatment-naive patients delaying retreatment beyond four months after one injection, and no intraocular inflammation at 2.5 mg. KLRS rose about 18% to $5.43.

Kalaris Therapeutics (NASDAQ:KLRS) shares rose about 29% after Phase 1a results for TH103 in neovascular age-related macular degeneration. The company reported vision and retinal anatomy improvements in expanded cohorts of 20 patients, with no intraocular inflammation at 2.5 mg and one transient case at 5 mg. TH103 showed lower Cmax versus leading anti-VEGF agents and longer retreatment intervals. Phase 1b/2 enrollment is ongoing, with initial data expected in H1 2027.

Kalaris Therapeutics (KLRS) reported expanded Phase 1a data for TH103 in neovascular age-related macular degeneration. The study included 17 treatment-naive and 3 treatment-experienced patients with 6-month follow-up. Plasma Cmax was 27 to 53 times lower than leading anti-VEGF agents, with 29% needing no anti-VEGF during follow-up. Safety showed no IOI at 2.5 mg and one transient IOI at 5 mg.

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.